The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Merck Sharp & Dohme BV,EU/1/06/357/01-21

Main Information

Trade NameGardasil
Active SubstancesQuadrivalent human papillomavirus type 11 recombinant vaccine (in)
Quadrivalent human papillomavirus type 16 recombinant vaccine (in)
Quadrivalent human papillomavirus type 18 recombinant vaccine (in)
Quadrivalent human papillomavirus type 6 recombinant vaccine
Dosage FormSuspension for injection
Licence HolderMerck Sharp & Dohme BV,
Licence NumberEU/1/06/357/01-21

Group Information

ATC CodeJ07BM01 papillomavirus (human types 6, 11, 16, 18)


License statusAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back